AveXis Announces Proposed Public Offering of 4,000,000 Shares of Common Stock
September 06 2016 - 4:00PM
AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer
and sell, subject to market conditions, 3,566,474 shares of its
common stock in an underwritten public offering. Additionally, PBM
Capital Investments, LLC, an existing stockholder of AveXis,
intends to offer and sell 433,526 shares in the proposed offering.
AveXis will not receive proceeds from the sale of the shares by the
selling stockholder. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or the actual size or terms of the
offering.
Goldman, Sachs & Co. and Jefferies LLC are acting as joint
book-running managers. BMO Capital Markets is acting as lead
manager and Chardan is acting as co-manager of the offering. AveXis
intends to grant the underwriters a 30-day option to purchase up to
an additional 600,000 shares of common stock at the public offering
price, less the underwriting discounts and commissions.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission but has not yet
become effective. These securities may not be sold nor may offers
to buy be accepted prior to the time the registration statement
becomes effective. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy any of these
securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such an offer, solicitation or sale
would be unlawful prior to registration or qualification under the
applicable securities laws of such state or jurisdiction.
The proposed offering will be made only by means of a
prospectus, copies of which may be obtained for free, when
available, from the offices of Goldman, Sachs & Co., Attention:
Prospectus Department, 200 West Street, New York, NY 10282; by
telephone at 1-866-471-2526; or by email at
prospectus-ny@ny.email.gs.com or Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022; by phone at 1-877-821-7388; or by email
at Prospectus_Department@Jefferies.com.
About AveXis, Inc.AveXis is a clinical-stage
gene therapy company developing treatments for patients suffering
from rare and life-threatening neurological genetic diseases. The
company’s initial proprietary gene therapy candidate, AVXS-101, is
in an ongoing Phase 1 clinical trial for the treatment of SMA Type
1.
Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
lbarbiero@w2ogroup.com
Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2023 to Jul 2024